Drugs / D3S-002
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05886920 | Jul 2023 → Aug 2028 expected | — | D3 Bio (Wuxi) Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D3S-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05886920 ↗ |
| Route | Oral | “D3S-002 administered orally.” NCT05886920 ↗ |